nach oben

10.05.2024 | Review

The efficiency of stem cell differentiation into functional beta cells for treating insulin-requiring diabetes: Recent advances and current challenges

verfasst von: Yunfei Luo, Peng Yu, Jianping Liu

Erschienen in: Endocrine

Einloggen, um Zugang zu erhalten

Abstract

In recent years, the potential of stem cells (SCs) to differentiate into various types of cells, including β-cells, has led to a significant boost in development. The efficiency of this differentiation process and the functionality of the cells post-transplantation are crucial factors for the success of stem cell therapy in diabetes. Herein, this article reviews the current advances and challenges faced by stem cell differentiation into functional β-cells for diabetes treatment. In vitro, researchers have sought to enhance the differentiation efficiency of functional β-cells by mimicking the normal pancreatic development process, using gene manipulation, pharmacological and culture conditions stimulation, three-dimensional (3D) and organoid culture, or sorting for functional β-cells based on mature islet cell markers. Furthermore, in vivo studies have also looked at suitable transplantation sites, the enhancement of the transplantation microenvironment, immune modulation, and vascular function reconstruction to improve the survival rate of functional β-cells, thereby enhancing the treatment of diabetes. Despite these advancements, developing stem cells to produce functional β-cells for efficacious diabetes treatment is a continuous research endeavor requiring significant multidisciplinary collaboration, for the stem-cell-derived beta cells to evolve into an effective cellular therapy.

L. Wang, W. Peng, Z. Zhao, M. Zhang, Z. Shi, Z. Song, X. Zhang, C. Li, Z. Huang, X. Sun, L. Wang, M. Zhou, J. Wu, Y. Wang, Prevalence and treatment of diabetes in China, 2013–2018. JAMA 326, 2498–2506 (2021). https://doi.org/10.1001/jama.2021.22208CrossRefPubMedPubMedCentral

W. Bielka, A. Przezak, P. Molęda, E. Pius-Sadowska, B. Machaliński, Double diabetes-when type 1 diabetes meets type 2 diabetes: definition, pathogenesis and recognition. Cardiovasc. Diabetol. 23, 62 (2024). https://doi.org/10.1186/s12933-024-02145-xCrossRefPubMedPubMedCentral

M. Lipsett, R. Aikin, M. Castellarin, S. Hanley, A.M. Jamal, S. Laganiere, L. Rosenberg, Islet neogenesis: a potential therapeutic tool in type 1 diabetes. Int. J. Biochem. Cell Biol. 38, 498–503 (2006). https://doi.org/10.1016/j.biocel.2005.08.022CrossRefPubMed

A. Cañibano-Hernández, L. Sáenz Del Burgo, A. Espona-Noguera, J. Ciriza, J.L. Pedraz, Current advanced therapy cell-based medicinal products for type-1-diabetes treatment. Int. J. Pharm. 543, 107–120 (2018). https://doi.org/10.1016/j.ijpharm.2018.03.041CrossRefPubMed

J.B. Sneddon, Q. Tang, P. Stock, J.A. Bluestone, S. Roy, T. Desai, M. Hebrok, Stem cell therapies for treating diabetes: progress and remaining challenges. Cell Stem Cell 22, 810–823 (2018). https://doi.org/10.1016/j.stem.2018.05.016CrossRefPubMedPubMedCentral

G. Pan, Y. Mu, L. Hou, J. Liu, Examining the therapeutic potential of various stem cell sources for differentiation into insulin-producing cells to treat diabetes. Annales d’endocrinologie 80, 47–53 (2019). https://doi.org/10.1016/j.ando.2018.06.1084CrossRefPubMed

J. Shen, Y. Cheng, Q. Han, Y. Mu, W. Han, Generating insulin-producing cells for diabetic therapy: existing strategies and new development. Ageing Res. Rev. 12, 469–478 (2013). https://doi.org/10.1016/j.arr.2013.01.001CrossRefPubMed

T. Farooq, K. Rehman, A. Hameed, M.S.H. Akash, Stem cell therapy and Type 1 Diabetes Mellitus: Treatment strategies and future perspectives. Adv. Exp. Med. Biol. 1084, 95–107 (2019). https://doi.org/10.1007/5584_2018_195CrossRefPubMed

H.S. Jun. Cell replacement and regeneration therapy for diabetes. Korean Diabetes J. 34, 77–83 (2010). https://doi.org/10.4093/kdj.2010.34.2.77CrossRefPubMedPubMedCentral

10.

S. Chen, K. Du, C. Zou, Current progress in stem cell therapy for type 1 diabetes mellitus. Stem Cell. Res. Ther. 11, 275 (2020). https://doi.org/10.1186/s13287-020-01793-6CrossRefPubMedPubMedCentral

11.

A. Citro, A. Neroni, C. Pignatelli, F. Campo, M. Policardi, M. Monieri, S. Pellegrini, E. Dugnani, F. Manenti, M.C. Maffia, L. Valla, E. Kemter, I. Marzinotto, C. Olgasi, A. Cucci, A. Follenzi, V. Lampasona, E. Wolf, L. Piemonti, Directed self-assembly of a xenogeneic vascularized endocrine pancreas for type 1 diabetes. Nat. Commun. 14, 878 (2023). https://doi.org/10.1038/s41467-023-36582-1CrossRefPubMedPubMedCentral

12.

D. Kim, Y. Gu, M. Ishii, M. Fujimiya, M. Qi, N. Nakamura, T. Yoshikawa, S. Sumi, K. Inoue, In vivo functioning and transplantable mature pancreatic islet-like cell clusters differentiated from embryonic stem cell. Pancreas 27, e34–e41 (2003). https://doi.org/10.1097/00006676-200308000-00021CrossRefPubMed

13.

A. Rezania, J.E. Bruin, M.J. Riedel, M. Mojibian, A. Asadi, J. Xu, R. Gauvin, K. Narayan, F. Karanu, J.J. O’Neil, Z. Ao, G.L. Warnock, T.J. Kieffer, Maturation of human embryonic stem cell-derived pancreatic progenitors into functional islets capable of treating pre-existing diabetes in mice. Diabetes. 61, 2016–2029 (2012). https://doi.org/10.2337/db11-1711CrossRefPubMedPubMedCentral

14.

J.J. Heit, S.K. Kim, Embryonic stem cells and islet replacement in diabetes mellitus. Pediatr. Diabetes 5, 5–15 (2004). https://doi.org/10.1111/j.1399-543X.2004.00074.xCrossRefPubMed

15.

L. Sui, N. Danzl, S.R. Campbell, R. Viola, D. Williams, Y. Xing, Y. Wang, N. Phillips, G. Poffenberger, B. Johannesson, J. Oberholzer, A.C. Powers, R.L. Leibel, X. Chen, M. Sykes, D. Egli, Beta-cell replacement in mice using human Type 1 Diabetes nuclear transfer embryonic stem cells. Diabetes 67, 26–35 (2018). https://doi.org/10.2337/db17-0120CrossRefPubMed

16.

P. Torre P., A.I. Flores, Current status and future prospects of perinatal stem cells. Genes. 12 (2020). https://doi.org/10.3390/genes12010006

17.

K.C. Chao, K.F. Chao, Y.S. Fu, S.H. Liu, Islet-like clusters derived from mesenchymal stem cells in Wharton’s Jelly of the human umbilical cord for transplantation to control type 1 diabetes. PLoS One 3, e1451 (2008). https://doi.org/10.1371/journal.pone.0001451CrossRefPubMedPubMedCentral

18.

S. Sarang, C. Viswanathan, Umbilical cord derived mesenchymal stem cells useful in insulin production - another opportunity in cell therapy. Int. J. Stem Cells 9, 60–69 (2016). https://doi.org/10.15283/ijsc.2016.9.1.60CrossRefPubMedPubMedCentral

19.

S.S. Kadam, M. Sudhakar, P.D. Nair, R.R. Bhonde, Reversal of experimental diabetes in mice by transplantation of neo-islets generated from human amnion-derived mesenchymal stromal cells using immuno-isolatory macrocapsules. Cytotherapy 12, 982–991 (2010). https://doi.org/10.3109/14653249.2010.509546CrossRefPubMed

20.

Y. Zhao, B. Lin, M. Dingeldein, C. Guo, D. Hwang, M.J. Holterman, New type of human blood stem cell: a double-edged sword for the treatment of type 1 diabetes. Transl. Res. 155, 211–216 (2010). https://doi.org/10.1016/j.trsl.2010.01.003CrossRefPubMed

21.

M. El-Sherbiny, M.A. Eladl, A.V. Ranade, M. Guimei, H. Gabr, Functional beta-cells derived from umbilical cord blood mesenchymal stem cells for curing rats with streptozotocin-induced diabetes mellitus. Singapore Med. J. 61, 39–45 (2020). https://doi.org/10.11622/smedj.2019120CrossRefPubMedPubMedCentral

22.

X.P. Mu, L.Q. Ren, H.W. Yan, X.M. Zhang, T.M. Xu, A.H. Wei, J.L. Jiang, Enhanced differentiation of human amniotic fluid-derived stem cells into insulin-producing cells in vitro. J. Diabetes Investig. 8, 34–43 (2017). https://doi.org/10.1111/jdi.12544CrossRefPubMed

23.

C.N. Street, S. Sipione, L. Helms, T. Binette, R.V. Rajotte, R.C. Bleackley, G.S. Korbutt, Stem cell-based approaches to solving the problem of tissue supply for islet transplantation in type 1 diabetes. Int. J. Biochem. Cell Biol. 36, 667–683 (2004). https://doi.org/10.1016/j.biocel.2003.09.005CrossRefPubMed

24.

M. Li, S. Ikehara, Bone marrow stem cell as a potential treatment for diabetes. J. Diabetes Res. 2013, 329596 (2013). https://doi.org/10.1155/2013/329596CrossRefPubMedPubMedCentral

25.

E.M. Kang, P.P. Zickler, S. Burns, S.M. Langemeijer, S. Brenner, O.A. Phang, N. Patterson, D. Harlan, J.F. Tisdale, Hematopoietic stem cell transplantation prevents diabetes in NOD mice but does not contribute to significant islet cell regeneration once disease is established. Exp. Hematol. 33, 699–705 (2005). https://doi.org/10.1016/j.exphem.2005.03.008CrossRefPubMed

26.

M.M. Gabr, M.M. Zakaria, A.F. Refaie, E.A. Abdel-Rahman, A.M. Reda, S.S. Ali, S.M. Khater, S.A. Ashamallah, A.M. Ismail, H.E.A. Ismail, N. El-Badri, M.A. Ghoneim, From human mesenchymal stem cells to insulin-producing cells: comparison between bone marrow- and adipose tissue-derived cells. Biomed Res Int 2017, 3854232 (2017). https://doi.org/10.1155/2017/3854232CrossRefPubMedPubMedCentral

27.

L.J. Yang, Liver stem cell-derived beta-cell surrogates for treatment of type 1 diabetes. Autoimmun. Rev. 5, 409–413 (2006). https://doi.org/10.1016/j.autrev.2005.10.009CrossRefPubMed

28.

A.B. Peck, J.G. Cornelius, M. Chaudhari, D. Shatz, V.K. Ramiya, Use of in vitro-generated, stem cell-derived islets to cure type 1 diabetes: how close are we? Ann. N. Y. Acad. Sci. 958, 59–68 (2002). https://doi.org/10.1111/j.1749-6632.2002.tb02947.xCrossRefPubMed

29.

S. Kodama, D.L. Faustman, Routes to regenerating islet cells: stem cells and other biological therapies for type 1 diabetes. Pediatr. Diabetes 5, 38–44 (2004). https://doi.org/10.1111/j.1399-543X.2004.00078.xCrossRefPubMed

30.

V. Chandra, G.S. Phadnis, P.D. Nair, R.R. Bhonde, Generation of pancreatic hormone-expressing islet-like cell aggregates from murine adipose tissue-derived stem cells. Stem Cells 27, 1941–1953 (2009). https://doi.org/10.1002/stem.117CrossRefPubMed

31.

V. Chandra, G. Swetha, S. Muthyala, A.K. Jaiswal, J.R. Bellare, P.D. Nair, R.R. Bhonde, Islet-like cell aggregates generated from human adipose tissue derived stem cells ameliorate experimental diabetes in mice. PLoS One 6, e20615 (2011). https://doi.org/10.1371/journal.pone.0020615CrossRefPubMedPubMedCentral

32.

H.P. Lin, T.M. Chan, R.H. Fu, C.P. Chuu, S.C. Chiu, Y.H. Tseng, S.P. Liu, K.C. Lai, M.C. Shih, Z.S. Lin, H.S. Chen, D.C. Yeh, S.Z. Lin, Applicability of adipose-derived stem cells in type 1 diabetes mellitus. Cell Transplant. 24, 521–532 (2015). https://doi.org/10.3727/096368915X686977CrossRefPubMed

33.

Z. Eydian, A. Mohammad Ghasemi, S. Ansari, A.N. Kamali, M. Khosravi, S. Momtaz, S. Riki, L. Rafighdoost, R. Entezari Heravi, Differentiation of multipotent stem cells to insulin-producing cells for treatment of diabetes mellitus: bone marrow- and adipose tissue-derived cells comparison. Mol. Biol. Rep. 49, 3539–3548 (2022). https://doi.org/10.1007/s11033-022-07194-7CrossRefPubMed

34.

K.C. Lan, C.C. Wang, Y.P. Yen, R.S. Yang, S.H. Liu, D.C. Chan, Islet-like clusters derived from skeletal muscle-derived stem/progenitor cells for autologous transplantation to control type 1 diabetes in mice. Artif. Cells Nanomed. Biotechnol. 46, S328–S335 (2018). https://doi.org/10.1080/21691401.2018.1492421CrossRefPubMed

35.

A.N. Balamurugan, B. Naziruddin, A. Lockridge, M. Tiwari, G. Loganathan, M. Takita, S. Matsumoto, K. Papas, M. Trieger, H. Rainis, T. Kin, T.W. Kay, S. Wease, S. Messinger, C. Ricordi, R. Alejandro, J. Markmann, J. Kerr-Conti, M.R. Rickels, C. Liu, X. Zhang, P. Witkowski, A. Posselt, P. Maffi, A. Secchi, T. Berney, P.J. O’Connell, B.J. Hering, F.B. Barton, Islet product characteristics and factors related to successful human islet transplantation from the Collaborative Islet Transplant Registry (CITR) 1999-2010. Am. J. Transplant. 14, 2595–2606 (2014). https://doi.org/10.1111/ajt.12872CrossRefPubMedPubMedCentral

36.

J. Fujikura, K. Hosoda, K. Nakao, Cell transplantation therapy for diabetes mellitus: endocrine pancreas and adipocyte. Endocr. J. 60, 697–708 (2013). https://doi.org/10.1507/endocrj.ej13-0162CrossRefPubMed

37.

A. Soejitno, P.K. Prayudi, The prospect of induced pluripotent stem cells for diabetes mellitus treatment. Ther. Adv. Endocrinol. Metab. 2, 197–210 (2011). https://doi.org/10.1177/2042018811420198CrossRefPubMedPubMedCentral

38.

B. Soria, F.J. Bedoya, J.R. Tejedo, A. Hmadcha, R. Ruiz-Salmeron, S. Lim, F. Martin, Cell therapy for diabetes mellitus: an opportunity for stem cells? Cells Tissues Organs 188, 70–77 (2008). https://doi.org/10.1159/000119407CrossRefPubMed

39.

L.N. Randolph, A. Bhattacharyya, X.L. Lian, Human beta cells generated from pluripotent stem cells or cellular reprogramming for curing diabetes. Regen. Eng. Transl. Med. 5, 42–52 (2019). https://doi.org/10.1007/s40883-018-0082-yCrossRefPubMed

40.

X. Liu, Y. Wang, Y. Li, X. Pei, Research status and prospect of stem cells in the treatment of diabetes mellitus. Sci. China Life Sci. 56, 306–312 (2013). https://doi.org/10.1007/s11427-013-4469-1CrossRefPubMed

41.

H.A. Russ, S. Efrat, Development of human insulin-producing cells for cell therapy of diabetes. Pediatr. Endocrinol. Rev. 9, 590–597 (2011)PubMed

42.

M.M. Santosa, B.S. Low, N.M. Pek, A.K. Teo, Knowledge gaps in rodent pancreas biology: taking human pluripotent stem cell-derived pancreatic beta cells into our own hands. Front. Endocrinol. 6, 194 (2015). https://doi.org/10.3389/fendo.2015.00194CrossRef

43.

P. Wang, N.M. Fiaschi-Taesch, R.C. Vasavada, D.K. Scott, A. Garcia-Ocana, A.F. Stewart, Diabetes mellitus–advances and challenges in human beta-cell proliferation. Nat. Rev. Endocrinol. 11, 201–212 (2015). https://doi.org/10.1038/nrendo.2015.9CrossRefPubMed

44.

S.G. Rane, J.H. Lee, H.M. Lin, Transforming growth factor-beta pathway: role in pancreas development and pancreatic disease. Cytokine Growth Factor Rev. 17, 107–119 (2006). https://doi.org/10.1016/j.cytogfr.2005.09.003CrossRefPubMed

45.

A. Rezania, J.E. Bruin, P. Arora, A. Rubin, I. Batushansky, A. Asadi, S. O’Dwyer, N. Quiskamp, M. Mojibian, T. Albrecht, Y.H. Yang, J.D. Johnson, T.J. Kieffer, Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat. Biotechnol. 32, 1121–1133 (2014). https://doi.org/10.1038/nbt.3033CrossRefPubMed

46.

M. Rhinn, P. Dollé, Retinoic acid signalling during development. Development 139, 843–858 (2012). https://doi.org/10.1242/dev.065938CrossRefPubMed

47.

T.C. Schulz, H.Y. Young, A.D. Agulnick, M.J. Babin, E.E. Baetge, A.G. Bang, A. Bhoumik, I. Cepa, R.M. Cesario, C. Haakmeester, K. Kadoya, J.R. Kelly, J. Kerr, L.A. Martinson, A.B. McLean, M.A. Moorman, J.K. Payne, M. Richardson, K.G. Ross, E.S. Sherrer, X. Song, A.Z. Wilson, E.P. Brandon, C.E. Green, E.J. Kroon, O.G. Kelly, K.A. D’Amour, A.J. Robins, A scalable system for production of functional pancreatic progenitors from human embryonic stem cells. PLoS One 7, e37004 (2012). https://doi.org/10.1371/journal.pone.0037004CrossRefPubMedPubMedCentral

48.

J. Jensen, E.E. Pedersen, P. Galante, J. Hald, R.S. Heller, M. Ishibashi, R. Kageyama, F. Guillemot, P. Serup, O.D. Madsen, Control of endodermal endocrine development by Hes-1. Nat. Genet. 24, 36–44 (2000). https://doi.org/10.1038/71657CrossRefPubMed

49.

A. Apelqvist, H. Li, L. Sommer, P. Beatus, D.J. Anderson, T. Honjo, M. Hrabe de Angelis, U. Lendahl, H. Edlund, Notch signalling controls pancreatic cell differentiation. Nature. 400, 877–881 (1999). https://doi.org/10.1038/23716CrossRefPubMed

50.

L.C. Murtaugh, B.Z. Stanger, K.M. Kwan, D.A. Melton, Notch signaling controls multiple steps of pancreatic differentiation. Proc. Natl Acad. Sci. USA 100, 14920–14925 (2003). https://doi.org/10.1073/pnas.2436557100CrossRefPubMedPubMedCentral

51.

S.Y. Chun, D.L. Mack, E. Moorefield, S.H. Oh, T.G. Kwon, M.J. Pettenati, J.J. Yoo, P.D. Coppi, A. Atala, S. Soker, Pdx1 and controlled culture conditions induced differentiation of human amniotic fluid-derived stem cells to insulin-producing clusters. J. Tissue Eng. Regener. Med. 9, 540–549 (2015). https://doi.org/10.1002/term.1631CrossRef

52.

W. Nishimura, H. Iwasa, M. Tumurkhuu, Role of the transintenance of pancreatic β-cells. Int. J. Mol. Sci. 23 (2022). https://doi.org/10.3390/ijms23094478

53.

M.A. Huotari, P.J. Miettinen, J. Palgi, T. Koivisto, J. Ustinov, D. Harari, Y. Yarden, T. Otonkoski, ErbB signaling regulates lineage determination of developing pancreatic islet cells in embryonic organ culture. Endocrinology. 143, 4437–4446 (2002). https://doi.org/10.1210/en.2002-220382CrossRefPubMed

54.

Y.M. Cho, J.M. Lim, D.H. Yoo, J.H. Kim, S.S. Chung, S.G. Park, T.H. Kim, S.K. Oh, Y.M. Choi, S.Y. Moon, K.S. Park, H.K. Lee, Betacellulin and nicotinamide sustain PDX1 expression and induce pancreatic beta-cell differentiation in human embryonic stem cells. Biochem. Biophys. Res. Commun. 366, 129–134 (2008). https://doi.org/10.1016/j.bbrc.2007.11.112CrossRefPubMed

55.

B. Rajaei, M. Shamsara, L.M. Amirabad, M. Massumi, M.H. Sanati, Pancreatic Endoderm-derived from diabetic patient-specific induced pluripotent stem cell generates glucose-responsive insulin-secreting cells. J. Cell Physiol. 232, 2616–2625 (2017). https://doi.org/10.1002/jcp.25459CrossRefPubMed

56.

M.F. Abazari, N. Nasiri, F. Nejati, S. Zare Karizi, M. Amini Faskhodi, E. Saburi, N. Aghapur, M.R. Mahdavi, A. Ardeshirylajimi, S.E. Enderami, F. Soleimanifar, Comparison of human-induced pluripotent stem cells and mesenchymal stem cell differentiation potential to insulin producing cells in 2D and 3D culture systems in vitro. J. Cell Physiol. 235, 4239–4246 (2020). https://doi.org/10.1002/jcp.29298CrossRefPubMed

57.

B. Bose, S.P. Shenoy, S. Konda, P. Wangikar, Human embryonic stem cell differentiation into insulin secreting β-cells for diabetes. Cell Biol. Int. 36, 1013–1020 (2012). https://doi.org/10.1042/cbi20120210CrossRefPubMed

58.

J.H. Shim, S.E. Kim, D.H. Woo, S.K. Kim, C.H. Oh, R. McKay, J.H. Kim, Directed differentiation of human embryonic stem cells towards a pancreatic cell fate. Diabetologia. 50, 1228–1238 (2007). https://doi.org/10.1007/s00125-007-0634-zCrossRefPubMed

59.

A. El-Badawy, N. El-Badri, The cell cycle as a brake for beta-cell regeneration from embryonic stem cells. Stem Cell. Res. Ther. 7, 9 (2016). https://doi.org/10.1186/s13287-015-0274-zCrossRefPubMedPubMedCentral

60.

R. Faast, J. White, P. Cartwright, L. Crocker, B. Sarcevic, S. Dalton, Cdk6-cyclin D3 activity in murine ES cells is resistant to inhibition by p16(INK4a). Oncogene. 23, 491–502 (2004). https://doi.org/10.1038/sj.onc.1207133CrossRefPubMed

61.

A. Calder, I. Roth-Albin, S. Bhatia, C. Pilquil, J.H. Lee, M. Bhatia, M. Levadoux-Martin, J. McNicol, J. Russell, T. Collins, J.S. Draper, Lengthened G1 phase indicates differentiation status in human embryonic stem cells. Stem Cells Dev. 22, 279–295 (2013). https://doi.org/10.1089/scd.2012.0168CrossRefPubMed

62.

M.E. Bechard, C.V. Wright, New ideas connecting the cell cycle and pancreatic endocrine-lineage specification. Cell Cycle 16, 301–303 (2017). https://doi.org/10.1080/15384101.2016.1256149CrossRefPubMed

63.

E. Stead, J. White, R. Faast, S. Conn, S. Goldstone, J. Rathjen, U. Dhingra, P. Rathjen, D. Walker, S. Dalton, Pluripotent cell division cycles are driven by ectopic Cdk2, cyclin A/E and E2F activities. Oncogene. 21, 8320–8333 (2002). https://doi.org/10.1038/sj.onc.1206015CrossRefPubMed

64.

R.V. Mettus, S.G. Rane, Characterization of the abnormal pancreatic development, reduced growth and infertility in Cdk4 mutant mice. Oncogene. 22, 8413–8421 (2003). https://doi.org/10.1038/sj.onc.1206888CrossRefPubMed

65.

T. Otonkoski, New tools for experimental diabetes research: Cellular reprogramming and genome editing. Ups J. Med. Sci. 121, 146–150 (2016). https://doi.org/10.3109/03009734.2016.1149529CrossRefPubMedPubMedCentral

66.

K.F. Leavens, J.R. Alvarez-Dominguez, L.T. Vo, H.A. Russ, A.V. Parent, Stem cell-based multi-tissue platforms to model human autoimmune diabetes. Mol. Metab. 66, 101610 (2022). https://doi.org/10.1016/j.molmet.2022.101610CrossRefPubMedPubMedCentral

67.

S. Balakrishnan, S. Dhavamani, C. Prahalathan, beta-Cell specific transcription factors in the context of diabetes mellitus and beta-cell regeneration. Mech. Dev. 163, 103634 (2020). https://doi.org/10.1016/j.mod.2020.103634CrossRefPubMed

68.

Z.Y. Sun, T.Y. Yu, F.X. Jiang, W. Wang. Functional maturation of immature beta cells: A roadblock for stem cell therapy for type 1 diabetes. World J. Stem Cells. 26 (3), 193–207 (2021). https://doi.org/10.4252/wjsc.v13.i3.193

69.

B. Rajaei, M. Shamsara, M.H. Sanati, In vitro generation of glucose-responsive insulin-secreting cells from PDX1-overexpressing human-induced Pluripotent stem cell derived from diabetic patient. ASAIO J. 64, 819–826 (2018). https://doi.org/10.1097/MAT.0000000000000728CrossRefPubMed

70.

D. Dayer, M.R. Tabandeh, E. Moghimipour, M. Hashemi Tabar, A. Ghadiri, E. Allah Bakhshi, M. Orazizadeh, M.A. Ghafari, MafA overexpression: a new efficient protocol for in vitro differentiation of adipose-derived mesenchymal stem cells into functional insulin-producing cells. Cell J. 21, 169–178 (2019). https://doi.org/10.22074/cellj.2019.5669CrossRefPubMedPubMedCentral

71.

D. Gao, P. Dai, Z. Fan, J. Wang, Y. Zhang, The roles of different multigene combinations of Pdx1, Ngn3, Sox9, Pax4, and Nkx2.2 in the reprogramming of canine ADSCs into IPCs. Cell Transpl. 31, 9636897221081483 (2022). https://doi.org/10.1177/09636897221081483CrossRef

72.

L. Velazco-Cruz, M.M. Goedegebuure, K.G. Maxwell, P. Augsornworawat, N.J. Hogrebe, J.R. Millman, SIX2 regulates human beta cell differentiation from stem cells and functional maturation in vitro. Cell Rep. 31, 107687 (2020). https://doi.org/10.1016/j.celrep.2020.107687CrossRefPubMedPubMedCentral

73.

A. Diane, N.A. Al-Shukri, U.M.R. Bin Abdul Mu, H.H. Al-Siddiqi, Beta-cell mitochondria in diabetes mellitus: a missing puzzle piece in the generation of hPSC-derived pancreatic beta-cells? J. Transl. Med. 20, 163 (2022). https://doi.org/10.1186/s12967-022-03327-5CrossRefPubMedPubMedCentral

74.

J.C. Davis, T.C. Alves, A. Helman, J.C. Chen, J.H. Kenty, R.L. Cardone, D.R. Liu, R.G. Kibbey, D.A. Melton, Glucose response by stem cell-derived beta cells in vitro is inhibited by a bottleneck in glycolysis. Cell Rep. 31, 107623 (2020). https://doi.org/10.1016/j.celrep.2020.107623CrossRefPubMedPubMedCentral

75.

L. Lu, L. Zhitao, C. Nannan, H. Mingzhu, H. Xiaoping, H. Dongsheng, P. Zongfu, L. Xiaoyang, Mitofusin2 promotes beta cell maturation from mouse embryonic stem cells via Sirt3/Idh2 activation. Stem Cells Int. 2022, 1172795 (2022). https://doi.org/10.1155/2022/1172795CrossRefPubMedPubMedCentral

76.

Q. Ma, Y. Xiao, W. Xu, M. Wang, S. Li, Z. Yang, M. Xu, T. Zhang, Z.N. Zhang, R. Hu, Q. Su, F. Yuan, T. Xiao, X. Wang, Q. He, J. Zhao, Z.J. Chen, Z. Sheng, M. Chai, H. Wang, W. Shi, Q. Deng, X. Cheng, W. Li, ZnT8 loss-of-function accelerates functional maturation of hESC-derived beta cells and resists metabolic stress in diabetes. Nat. Commun. 13, 4142 (2022). https://doi.org/10.1038/s41467-022-31829-9CrossRefPubMedPubMedCentral

77.

E. Yoshihara, C. O’Connor, E. Gasser, Z. Wei, T.G. Oh, T.W. Tseng, D. Wang, F. Cayabyab, Y. Dai, R.T. Yu, C. Liddle, A.R. Atkins, M. Downes, R.M. Evans, Immune-evasive human islet-like organoids ameliorate diabetes. Nature. 586, 606–611 (2020). https://doi.org/10.1038/s41586-020-2631-zCrossRefPubMedPubMedCentral

78.

L.T. Lock, E.S. Tzanakakis, Stem/Progenitor cell sources of insulin-producing cells for the treatment of diabetes. Tissue Eng. 13, 1399–1412 (2007). https://doi.org/10.1089/ten.2007.0047CrossRefPubMed

79.

J.R. Benthuysen, A.C. Carrano, M. Sander, Advances in beta cell replacement and regeneration strategies for treating diabetes. J Clin Invest. 126, 3651–3660 (2016). https://doi.org/10.1172/JCI87439CrossRefPubMedPubMedCentral

80.

S. Chen, M. Borowiak, J.L. Fox, R. Maehr, K. Osafune, L. Davidow, K. Lam, L.F. Peng, S.L. Schreiber, L.L. Rubin, D. Melton, A small molecule that directs differentiation of human ESCs into the pancreatic lineage. Nat. Chem. Biol. 5, 258–265 (2009). https://doi.org/10.1038/nchembio.154CrossRefPubMed

81.

T.K. Kim, J.S. Lee, H.S. Jung, T.K. Ha, S.M. Kim, N. Han, E.J. Lee, T.N. Kim, M.J. Kwon, S.H. Lee, M.K. Kim, B.D. Rhee, J.H. Park, Triiodothyronine induces proliferation of pancreatic β-cells through the MAPK/ERK pathway. Exp. Clin. Endocrinol. Diabetes 122, 240–245 (2014). https://doi.org/10.1055/s-0034-1367060CrossRefPubMed

82.

S. Misiti, E. Anastasi, S. Sciacchitano, C. Verga Falzacappa, L. Panacchia, B. Bucci, D. Khouri, I. D’Acquarica, E. Brunetti, U. Di Mario, V. Toscano, R. Perfetti, 3,5,3’-Triiodo-L-thyronine enhances the differentiation of a human pancreatic duct cell line (hPANC-1) towards a beta-cell-Like phenotype. J. Cell Physiol. 204, 286–296 (2005). https://doi.org/10.1002/jcp.20293CrossRefPubMed

83.

F.X. Jiang, K. Li, M. Archer, M. Mehta, E. Jamieson, A. Charles, J.E. Dickinson, M. Matsumoto, G. Morahan, Differentiation of IsleT progenitors regulated by Nicotinamide into Transcriptome-verified beta cells that ameliorate diabetes. Stem Cells 35, 1341–1354 (2017). https://doi.org/10.1002/stem.2567CrossRefPubMed

84.

M.C. Gaudreau, R.R. Gudi, G. Li, B.M. Johnson, C. Vasu, Gastrin producing syngeneic mesenchymal stem cells protect non-obese diabetic mice from type 1 diabetes. Autoimmunity 55, 95–108 (2022). https://doi.org/10.1080/08916934.2021.2012165CrossRefPubMed

85.

T. Dahan, O. Ziv, E. Horwitz, H. Zemmour, J. Lavi, A. Swisa, G. Leibowitz, F.M. Ashcroft, P. In’t Veld, B. Glaser, Y. Dor, Pancreatic β-cells express the fetal islet hormone gastrin in rodent and human diabetes. Diabetes. 66, 426–436 (2017). https://doi.org/10.2337/db16-0641CrossRefPubMed

86.

X. Ma, Y. Lu, Z. Zhou, Q. Li, X. Chen, W. Wang, Y. Jin, Z. Hu, G. Chen, Q. Deng, W. Shang, H. Wang, H. Fu, X. He, X.H. Feng, S. Zhu, Human expandable pancreatic progenitor-derived beta cells ameliorate diabetes. Sci. Adv. 8, eabk1826 (2022). https://doi.org/10.1126/sciadv.abk1826CrossRefPubMedPubMedCentral

87.

E. Shin, T.Y. Kwon, Y. Cho, Y. Kim, J.H. Shin, Y.M. Han, ECM architecture-mediated regulation of β-cell differentiation from hESCs via Hippo-independent YAP activation. ACS Biomater. Sci. Eng. 9, 680–692 (2023). https://doi.org/10.1021/acsbiomaterials.2c01054CrossRefPubMed

88.

S. Cechin, S. Alvarez-Cubela, J.A. Giraldo, R.D. Molano, S. Villate, C. Ricordi, A. Pileggi, L. Inverardi, C.A. Fraker, J. Dominguez-Bendala, Influence of in vitro and in vivo oxygen modulation on beta cell differentiation from human embryonic stem cells. Stem Cells Transl. Med. 3, 277–289 (2014). https://doi.org/10.5966/sctm.2013-0160CrossRefPubMed

89.

B. Xu, D. Fan, Y. Zhao, J. Li, Z. Wang, J. Wang, X. Wang, Z. Guan, B. Niu, Three-dimensional culture promotes the differentiation of human dental pulp mesenchymal stem cells into insulin-producing cells for improving the diabetes therapy. Front. Pharmacol. 10, 1576 (2019). https://doi.org/10.3389/fphar.2019.01576CrossRefPubMed

90.

J. Chmielowiec, M. Borowiak. In vitro differentiation and expansion of human pluripotent stem cell-derived pancreatic progenitors. Rev. Diabet. Stud. Spring 11, 19–34 (2014). https://doi.org/10.1900/RDS.2014.11.19CrossRef

91.

K. Kalra, S.T. Chandrabose, T.S. Ramasamy, N. Kasim, Advances in the generation of functional beta-cells from induced pluripotent stem cells as a cure for diabetes mellitus. Curr. Drug Targets 19, 1463–1477 (2018). https://doi.org/10.2174/1389450119666180605112917CrossRefPubMed

92.

Q. Wang, W. Donelan, H. Ye, Y. Jin, Y. Lin, X. Wu, Y. Wang, Y. Xi, Real-time observation of pancreatic beta cell differentiation from human induced pluripotent stem cells. Am. J. Transl. Res. 11, 3490–3504 (2019)PubMedPubMedCentral

93.

F. Lebreton, V. Lavallard, K. Bellofatto, R. Bonnet, C.H. Wassmer, L. Perez, V. Kalandadze, A. Follenzi, M. Boulvain, J. Kerr-Conte, D.J. Goodman, D. Bosco, T. Berney, E. Berishvili, Insulin-producing organoids engineered from islet and amniotic epithelial cells to treat diabetes. Nat. Commun. 10, 4491 (2019). https://doi.org/10.1038/s41467-019-12472-3CrossRefPubMedPubMedCentral

94.

X. Zhang, Z. Ma, E. Song, T. Xu, Islet organoid as a promising model for diabetes. Protein Cell 13, 239–257 (2022). https://doi.org/10.1007/s13238-021-00831-0CrossRefPubMed

95.

C.H. Wassmer, F. Lebreton, K. Bellofatto, L. Perez, D. Cottet-Dumoulin, A. Andres, D. Bosco, T. Berney, V. Othenin-Girard, B. Martinez De Tejada, M. Cohen, C. Olgasi, A. Follenzi, E. Berishvili, Bio-engineering of pre-vascularized islet organoids for the treatment of Type 1 Diabetes. Transpl. Int. 35, 10214 (2021). https://doi.org/10.3389/ti.2021.10214CrossRefPubMed

96.

F. Lebreton, K. Bellofatto, C.H. Wassmer, L. Perez, V. Lavallard, G. Parnaud, D. Cottet-Dumoulin, J. Kerr-Conte, F. Pattou, D. Bosco, V. Othenin-Girard, B. Martinez de Tejada, E. Berishvili, Shielding islets with human amniotic epithelial cells enhances islet engraftment and revascularization in a murine diabetes model. Am. J. Transpl. 20, 1600–6143 (Electronic), 1551–1561 (2020).

97.

S. Pellegrini, V. Zamarian, V. Sordi, Strategies to improve the safety of iPSC-derived beta cells for beta cell replacement in diabetes. Transpl. Int. 35, 10575 (2022). https://doi.org/10.3389/ti.2022.10575CrossRefPubMedPubMedCentral

98.

A. Rezania, J.E. Bruin, J. Xu, K. Narayan, J.K. Fox, J.J. O’Neil, T.J. Kieffer, Enrichment of human embryonic stem cell-derived NKX6.1-expressing pancreatic progenitor cells accelerates the maturation of insulin-secreting cells in vivo. Stem Cells 31, 2432–2442 (2013). https://doi.org/10.1002/stem.1489CrossRefPubMed

99.

F.M. Docherty, K.A. Riemondy, R. Castro-Gutierrez, J.M. Dwulet, A.H. Shilleh, M.S. Hansen, S.P.M. Williams, L.H. Armitage, K.E. Santostefano, M.A. Wallet, C.E. Mathews, T.M. Triolo, R.K.P. Benninger, H.A. Russ, ENTPD3 marks mature stem cell-derived beta-cells formed by self-aggregation in vitro. Diabetes 70, 2554–2567 (2021). https://doi.org/10.2337/db20-0873CrossRefPubMedPubMedCentral

100.

T. van der Meulen, M.O. Huising, Maturation of stem cell-derived beta-cells guided by the expression of urocortin 3. Rev. Diabet. Stud. Spring 11, 115–132 (2014). https://doi.org/10.1900/RDS.2014.11.115CrossRef

101.

D.H. Kassem, M.M. Kamal, L. El-Kholy Ael, H.O. El-Mesallamy, Association of expression levels of pluripotency/stem cell markers with the differentiation outcome of Wharton’s jelly mesenchymal stem cells into insulin producing cells. Biochimie 127, 187–195 (2016). https://doi.org/10.1016/j.biochi.2016.05.019CrossRefPubMed

102.

H.E. Arda, L. Li, J. Tsai, E.A. Torre, Y. Rosli, H. Peiris, R.C. Spitale, C. Dai, X. Gu, K. Qu, P. Wang, J. Wang, M. Grompe, R. Scharfmann, M.S. Snyder, R. Bottino, A.C. Powers, H.Y. Chang, S.K. Kim, Age-dependent pancreatic gene regulation reveals mechanisms governing human β cell function. Cell Metab. 23, 909–920 (2016). https://doi.org/10.1016/j.cmet.2016.04.002CrossRefPubMedPubMedCentral

103.

D. Balboa, D.G. Iworima, T.J. Kieffer, Human Pluripotent stem cells to model islet defects in diabetes. Front. Endocrinol. 12, 642152 (2021). https://doi.org/10.3389/fendo.2021.642152CrossRef

104.

P. Augsornworawat, K.G. Maxwell, L. Velazco-Cruz, J.R. Millman, Single-cell transcriptome profiling reveals β cell maturation in stem cell-derived islets after transplantation. Cell Rep. 32, 108067 (2020). https://doi.org/10.1016/j.celrep.2020.108067CrossRefPubMedPubMedCentral

105.

A. Veres, A.L. Faust, H.L. Bushnell, E.N. Engquist, J.H. Kenty, G. Harb, Y.C. Poh, E. Sintov, M. Gürtler, F.W. Pagliuca, Q.P. Peterson, D.A. Melton, Charting cellular identity during human in vitro β-cell differentiation. Nature 569, 368–373 (2019). https://doi.org/10.1038/s41586-019-1168-5CrossRefPubMedPubMedCentral

106.

F. Cayabyab, L.R. Nih, E. Yoshihara, Advances in pancreatic islet transplantation sites for the treatment of diabetes. Front. Endocrinol. 12, 732431 (2021). https://doi.org/10.3389/fendo.2021.732431CrossRef

107.

T. Kasputis, D. Clough, F. Noto, K. Rychel, B. Dye, L.D. Shea, Microporous polymer scaffolds for the transplantation of embryonic stem cell derived pancreatic progenitors to a clinically translatable site for the treatment of Type I diabetes. ACS Biomater. Sci. Eng. 4, 1770–1778 (2018). https://doi.org/10.1021/acsbiomaterials.7b00912CrossRefPubMedPubMedCentral

108.

X. Li, Z. Wei, L. Wu, H. Lv, Y. Zhang, J. Li, H. Yao, H. Zhang, B. Yang, X. Xu, J. Jiang, Efficacy of Fe(₃)O(₄)@polydopamine nanoparticle-labeled human umbilical cord Wharton’s jelly-derived mesenchymal stem cells in the treatment of streptozotocin-induced diabetes in rats. Biomater. Sci. 8, 5362–5375 (2020). https://doi.org/10.1039/d0bm01076fCrossRefPubMed

109.

A. Ramzy, P.J. Belmonte, M.J.S. Braam, S. Ida, E.M. Wilts, M.K. Levings, A. Rezania, T.J. Kieffer, A century-long journey from the discovery of insulin to the implantation of stem cell-derived islets. Endocr. Rev. 44, 222–253 (2023). https://doi.org/10.1210/endrev/bnac021CrossRefPubMed

110.

Tun SBB, M. Chua, R. Hasan, M. Köhler, X. Zheng, Y. Ali, M.H. Abdulreda, L. Juntti-Berggren, V.A. Barathi, P.O. Berggren, Islet transplantation to the anterior chamber of the Eye-A future treatment option for insulin-deficient Type-2 diabetics? A case report from a Nonhuman Type-2 diabetic primate. Cell Transpl. 29, 963689720913256 (2020). https://doi.org/10.1177/0963689720913256CrossRef

111.

T.J.I. Kieffer. Progress towards a stem cell based therapy for diabetes. J. Stem Cells Regen. Med. 17, 61 (2021). https://doi.org/10.46582/jsrm.1702010CrossRefPubMedPubMedCentral

112.

N. Sakata, T. Aoki, G. Yoshimatsu, H. Tsuchiya, T. Hata, Y. Katayose, S. Egawa, M. Unno, Strategy for clinical setting in intramuscular and subcutaneous islet transplantation. Diabetes Metab. Res. Rev. 30, 1–10 (2014). https://doi.org/10.1002/dmrr.2463CrossRefPubMed

113.

J.D. Weaver, D.M. Headen, J. Aquart, C.T. Johnson, L.D. Shea, H. Shirwan, A.J. García, Vasculogenic hydrogel enhances islet survival, engraftment, and function in leading extrahepatic sites. Sci. Adv. 3, e1700184 (2017). https://doi.org/10.1126/sciadv.1700184CrossRefPubMedPubMedCentral

114.

F. Van Hulle, K. De Groot, R. Hilbrands, U. Van de Velde, K. Suenens, G. Stangé, I. De Mesmaeker, D.L. De Paep, Z. Ling, B. Roep, P. Gillard, D. Pipeleers, B. Keymeulen, D. Jacobs-Tulleneers-Thevissen, Function and composition of pancreatic islet cell implants in omentum of type 1 diabetes patients. Am. J. Transpl. 22, 927–936 (2022). https://doi.org/10.1111/ajt.16884CrossRef

115.

D.L. Faustman, M. Davis, Stem cells in the spleen: therapeutic potential for Sjogren’s syndrome, type I diabetes, and other disorders. Int. J. Biochem. Cell Biol. 42, 1576–1579 (2010). https://doi.org/10.1016/j.biocel.2010.06.012CrossRefPubMedPubMedCentral

116.

M.S. Remedi, C. Emfinger, Pancreatic beta-cell identity in diabetes. Diabetes Obes. Metab. 18, 110–116 (2016). https://doi.org/10.1111/dom.12727.CrossRefPubMedPubMedCentral

117.

S. Yagihashi, W. Inaba, H. Mizukami, Dynamic pathology of islet endocrine cells in type 2 diabetes: beta-Cell growth, death, regeneration and their clinical implications. J. Diabetes Investig. 7, 155–165 (2016). https://doi.org/10.1111/jdi.12424CrossRefPubMed

118.

P.A. Halban, Cell therapy for type 2 diabetes: is it desirable and can we get it? Diabetes Obes. Metab. 10, 205–211 (2008). https://doi.org/10.1111/j.1463-1326.2008.00957.xCrossRefPubMed

119.

F. Fantuzzi, S. Toivonen, A.A. Schiavo, H. Chae, M. Tariq, T. Sawatani, N. Pachera, Y. Cai, C. Vinci, E. Virgilio, L. Ladriere, M. Suleiman, P. Marchetti, J.C. Jonas, P. Gilon, D.L. Eizirik, M. Igoillo-Esteve, M. Cnop, In depth functional characterization of human induced pluripotent stem cell-derived beta cells in vitro and in vivo. Front Cell Dev Biol 10, 967765 (2022). https://doi.org/10.3389/fcell.2022.967765CrossRefPubMedPubMedCentral

120.

N. Saber, J.E. Bruin, S. O’Dwyer, H. Schuster, A. Rezania, T.J. Kieffer, Sex differences in maturation of human embryonic stem cell-derived beta cells in mice. Endocrinology 159, 1827–1841 (2018). https://doi.org/10.1210/en.2018-00048CrossRefPubMed

121.

M. Zhao, S.A. Amiel, S. Ajami, J. Jiang, M. Rela, N. Heaton, G.C. Huang, Amelioration of streptozotocin-induced diabetes in mice with cells derived from human marrow stromal cells. PLoS One 3, e2666 (2008). https://doi.org/10.1371/journal.pone.0002666CrossRefPubMedPubMedCentral

122.

J.E. Bruin, A. Asadi, J.K. Fox, S. Erener, A. Rezania, T.J. Kieffer, Accelerated maturation of human stem cell-derived pancreatic progenitor cells into insulin-secreting cells in immunodeficient rats relative to mice. Stem Cell Rep. 5, 1081–1096 (2015). https://doi.org/10.1016/j.stemcr.2015.10.013CrossRef

123.

V. Sordi, L. Monaco, L. Piemonti, Cell therapy for type 1 diabetes: from islet transplantation to stem cells. Horm. Horm. Res. Paediatr. 96, 658–669 (2022). https://doi.org/10.1159/000526618CrossRefPubMed

124.

S. Pellegrini, L. Piemonti, V. Sordi, Pluripotent stem cell replacement approaches to treat type 1 diabetes. Curr Opin Pharmacol 43, 20–26 (2018). https://doi.org/10.1016/j.coph.2018.07.007CrossRefPubMed

125.

R.Y. Calne, M.A. Ghoneim, K.O. Lee, G.S. Uin, Gene and stem cell therapy for diabetes. Clin Transpl. 12, 111–112 (2013).

126.

E. de Klerk, M. Hebrok, Stem cell-based clinical trials for Diabetes Mellitus. Front. Endocrinol. 12, 631463 (2021). https://doi.org/10.3389/fendo.2021.631463CrossRef

127.

K. Kirk, E. Hao, R. Lahmy, P. Itkin-Ansari, Human embryonic stem cell derived islet progenitors mature inside an encapsulation device without evidence of increased biomass or cell escape. Stem Cell. Res. 12, 807–814 (2014). https://doi.org/10.1016/j.scr.2014.03.003CrossRefPubMed

128.

A.A. Tomei, C. Villa, C. Ricordi, Development of an encapsulated stem cell-based therapy for diabetes. Expert Opin. Biol. Ther. 15, 1321–1336 (2015). https://doi.org/10.1517/14712598.2015.1055242CrossRefPubMedPubMedCentral

129.

B.E. Tuch, T.C. Hughes, M.D. Evans, Encapsulated pancreatic progenitors derived from human embryonic stem cells as a therapy for insulin-dependent diabetes. Diabetes Metab. Res. Rev. 27, 928–932 (2011). https://doi.org/10.1002/dmrr.1274CrossRefPubMed

130.

A.J. Vegas, O. Veiseh, M. Gurtler, J.R. Millman, F.W. Pagliuca, A.R. Bader, J.C. Doloff, J. Li, M. Chen, K. Olejnik, H.H. Tam, S. Jhunjhunwala, E. Langan, S. Aresta-Dasilva, S. Gandham, J.J. McGarrigle, M.A. Bochenek, J. Hollister-Lock, J. Oberholzer, D.L. Greiner, G.C. Weir, D.A. Melton, R. Langer, D.G. Anderson, Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice. Nat. Med. 22, 306–311 (2016). https://doi.org/10.1038/nm.4030CrossRefPubMedPubMedCentral

131.

X. Wang, K.G. Maxwell, K. Wang, D.T. Bowers, J.A. Flanders, W. Liu, L.H. Wang, Q. Liu, C. Liu, A. Naji, Y. Wang, B. Wang, J. Chen, A.U. Ernst, J.M. Melero-Martin, J.R. Millman, M. Ma, A nanofibrous encapsulation device for safe delivery of insulin-producing cells to treat type 1 diabetes. Sci. Transl. Med. 13(2021). https://doi.org/10.1126/scitranslmed.abb4601

132.

R. Anzalone, M. Lo Iacono, T. Loria, A. Di Stefano, P. Giannuzzi, F. Farina, G. La Rocca, Wharton’s jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes. Stem Cell Rev. Rep. 7, 342–363 (2011). https://doi.org/10.1007/s12015-010-9196-4CrossRefPubMed

133.

W. Zhang, Q. Ling, B. Wang, K. Wang, J. Pang, J. Lu, Y. Bi, D. Zhu, Comparison of therapeutic effects of mesenchymal stem cells from umbilical cord and bone marrow in the treatment of type 1 diabetes. Stem Cell. Res. Ther. 13, 406 (2022). https://doi.org/10.1186/s13287-022-02974-1CrossRefPubMedPubMedCentral

134.

Q. Huang, Y. Huang, J. Liu, Mesenchymal stem cells: an excellent candidate for the treatment of Diabetes Mellitus. Int J Endocrinol 2021, 9938658 (2021). https://doi.org/10.1155/2021/9938658CrossRefPubMedPubMedCentral

135.

T.Y. Yeung, K.L. Seeberger, T. Kin, A. Adesida, N. Jomha, A.M. Shapiro, G.S. Korbutt, Human mesenchymal stem cells protect human islets from pro-inflammatory cytokines. PLoS One 7, e38189 (2012). https://doi.org/10.1371/journal.pone.0038189CrossRefPubMedPubMedCentral

136.

C. Fotino, C. Ricordi, V. Lauriola, R. Alejandro, A. Pileggi, Bone marrow-derived stem cell transplantation for the treatment of insulin-dependent diabetes. Rev. Diabet. Stud. Summer 7, 144–157 (2010). https://doi.org/10.1900/RDS.2010.7.144CrossRef

137.

Z. Azizi, R. Abbaszadeh, R. Sahebnasagh, A. Norouzy, E. Motevaseli, K. Maedler, Bone marrow mesenchymal stromal cells for diabetes therapy: touch, fuse, and fix? Stem Cell. Res. Ther. 13, 348 (2022). https://doi.org/10.1186/s13287-022-03028-2CrossRefPubMedPubMedCentral

138.

M. Haque, F. Lei, X. Xiong, J.K. Das, X. Ren, D. Fang, S. Salek-Ardakani, J.M. Yang, J. Song, Stem cell-derived tissue-associated regulatory T cells suppress the activity of pathogenic cells in autoimmune diabetes. JCI Insight. 4 (2019). https://doi.org/10.1172/jci.insight.126471

139.

Y.L. Sun, L.R. Shang, R.H. Liu, X.Y. Li, S.H. Zhang, Y.K. Ren, K. Fu, H.B. Cheng, B.H. Yahaya, Y.L. Liu, J.T. Lin, Therapeutic effects of menstrual blood-derived endometrial stem cells on mouse models of streptozotocin-induced type 1 diabetes. World J. Stem Cells 14, 104–116 (2022). https://doi.org/10.4252/wjsc.v14.i1.104CrossRefPubMedPubMedCentral

140.

E.J. Bassi, P.M. Moraes-Vieira, C.S. Moreira-Sa, D.C. Almeida, L.M. Vieira, C.S. Cunha, M.I. Hiyane, A.S. Basso, A. Pacheco-Silva, N.O. Camara, Immune regulatory properties of allogeneic adipose-derived mesenchymal stem cells in the treatment of experimental autoimmune diabetes. Diabetes 61, 2534–2545 (2012). https://doi.org/10.2337/db11-0844CrossRefPubMedPubMedCentral

141.

D.A. Alagpulinsa, J.J.L. Cao, D. Sobell, M.C. Poznansky, Harnessing CXCL12 signaling to protect and preserve functional beta-cell mass and for cell replacement in type 1 diabetes. Pharmacol. Ther. 193, 63–74 (2019). https://doi.org/10.1016/j.pharmthera.2018.08.011CrossRefPubMed

142.

E. Sintov, I. Nikolskiy, V. Barrera, J. Hyoje-Ryu Kenty, A.S. Atkin, D. Gerace, S.J. Ho Sui, K. Boulanger, D.A. Melton, Whole-genome CRISPR screening identifies genetic manipulations to reduce immune rejection of stem cell-derived islets. Stem Cell Rep. 17, 1976–1990 (2022). https://doi.org/10.1016/j.stemcr.2022.08.002CrossRef

143.

G.G. Gornalusse, R.K. Hirata, S.E. Funk, L. Riolobos, V.S. Lopes, G. Manske, D. Prunkard, A.G. Colunga, L.A. Hanafi, D.O. Clegg, C. Turtle, D.W. Russell, HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat. Biotechnol. 35, 765–772 (2017). https://doi.org/10.1038/nbt.3860CrossRefPubMedPubMedCentral

144.

S.D. Sackett, S.J. Kaplan, S.A. Mitchell, M.E. Brown, A.L. Burrack, S. Grey, D. Huangfu, J. Odorico, Genetic engineering of immune evasive stem cell-derived islets. Transpl. Int. 35, 10817 (2022). https://doi.org/10.3389/ti.2022.10817CrossRefPubMedPubMedCentral

145.

H.M. Shahjalal, A. Abdal Dayem, K.M. Lim, T.I. Jeon, S.G. Cho, Generation of pancreatic beta cells for treatment of diabetes: advances and challenges. Stem Cell. Res. Ther. 9, 355 (2018). https://doi.org/10.1186/s13287-018-1099-3CrossRefPubMedPubMedCentral

146.

E. Hajizadeh-Saffar, Y. Tahamtani, N. Aghdami, K. Azadmanesh, M. Habibi-Anbouhi, Y. Heremans, N. De Leu, H. Heimberg, P. Ravassard, M.A. Shokrgozar, H. Baharvand, Inducible VEGF expression by human embryonic stem cell-derived mesenchymal stromal cells reduces the minimal islet mass required to reverse diabetes. Sci Rep. 30, 9322 (2015). https://doi.org/10.1038/srep09322CrossRef

147.

M. Seno, M.C.I. Nostro, How can you choose the fate of iPSCs and stem cells, Regeneration or Carcinogenesis? A hypothetical insight.: II. Modelling human beta cell development with pluripotent stem cells. J. Stem Cells Regen. Med. 16, 90–91 (2020). https://doi.org/10.46582/jsrm.1602013CrossRefPubMedPubMedCentral

148.

J. Chen, H. Li, F. Addabbo, F. Zhang, E. Pelger, D. Patschan, H.C. Park, M.C. Kuo, J. Ni, G. Gobe, P.N. Chander, A. Nasjletti, M.S. Goligorsky, Adoptive transfer of syngeneic bone marrow-derived cells in mice with obesity-induced diabetes: selenoorganic antioxidant ebselen restores stem cell competence. Am. J. Pathol. 174, 701–711 (2009). https://doi.org/10.2353/ajpath.2009.080606CrossRefPubMedPubMedCentral

149.

K. Cierpka-Kmiec, A. Wronska, Z. Kmiec, In vitro generation of pancreatic beta-cells for diabetes treatment. I. beta-like cells derived from human pluripotent stem cells. Folia Histochem. Cytobiol. 57, 1–14 (2019). https://doi.org/10.5603/FHC.a2019.0001CrossRefPubMed

150.

J. Homma, H. Sekine, T. Shimizu, Tricultured cell sheets develop into functional pancreatic islet tissue with a vascular network. Tissue Eng. A 29, 211–224 (2023). https://doi.org/10.1089/ten.TEA.2022.0167CrossRef

151.

J. Yang, Y. Yan, X. Yin, X. Liu, I.V. Reshetov, P.A. Karalkin, Q. Li, R.L. Huang, Bioengineering and vascularization strategies for islet organoids: advancing toward diabetes therapy. Metabolism 152, 155786 (2024). https://doi.org/10.1016/j.metabol.2024.155786CrossRefPubMed

152.

C. Bandeiras, A.J. Hwa, J.M.S. Cabral, F.C. Ferreira, S.N. Finkelstein, R.A. Gabbay, Economics of Beta-cell replacement therapy. Curr. Diab. Rep. 19, 75 (2019). https://doi.org/10.1007/s11892-019-1203-9CrossRefPubMed

153.

G.G. Nair, E.S. Tzanakakis, M. Hebrok, Emerging routes to the generation of functional β-cells for diabetes mellitus cell therapy. Nat. Rev. Endocrinol. 16, 506–518 (2020). https://doi.org/10.1038/s41574-020-0375-3CrossRefPubMedPubMedCentral

154.

K. Wallner, R.G. Pedroza, I. Awotwe, J.M. Piret, P.A. Senior, Shapiro AMJ, C. McCabe, Stem cells and beta cell replacement therapy: a prospective health technology assessment study. BMC Endocr. Disord. 18, 6 (2018). https://doi.org/10.1186/s12902-018-0233-7CrossRefPubMedPubMedCentral

155.

C. Bandeiras, J.M.S. Cabral, R.A. Gabbay, S.N. Finkelstein, F.C. Ferreira, Bringing stem cell-based therapies for Type 1 diabetes to the clinic: early insights from bioprocess economics and cost-effectiveness analysis. Biotechnol. J. 14, e1800563 (2019). https://doi.org/10.1002/biot.201800563CrossRefPubMed

156.

T.C. Schulz, Concise review: manufacturing of pancreatic endoderm cells for clinical trials in Type 1 diabetes. Stem Cells Transl. Med. 4, 927–931 (2015). https://doi.org/10.5966/sctm.2015-0058CrossRefPubMedPubMedCentral

157.

S. Sepyani, S. Momenzadeh, S. Safabakhsh, R. Nedaeinia, R. Salehi, Therapeutic approaches for Type 1 Diabetes: Promising cell-based approaches to achieve ultimate success. SLAS Discov. Adv. Life Sci. R & D 29, 23–33 (2024). https://doi.org/10.1016/j.slasd.2023.11.002CrossRef

158.

N. Cuesta-Gomez, K. Verhoeff, I.T. Jasra, R. Pawlick, N. Dadheech, A.M.J. Shapiro, Characterization of stem-cell-derived islets during differentiation and after implantation. Cell Rep. 40, 111238 (2022). https://doi.org/10.1016/j.celrep.2022.111238CrossRefPubMed

159.

C.J. Burns, S.J. Persaud, P.M. Jones, Diabetes mellitus: a potential target for stem cell therapy. Curr. Stem Cell. Res. Ther. 1, 255–266 (2006). https://doi.org/10.2174/157488806776956832CrossRefPubMed

160.

A.L. Marquez-Aguirre, A.A. Canales-Aguirre, E. Padilla-Camberos, H. Esquivel-Solis, N.E. Diaz-Martinez, Development of the endocrine pancreas and novel strategies for beta-cell mass restoration and diabetes therapy. Braz. J. Med. Biol. Res. 48, 765–776 (2015). https://doi.org/10.1590/1414-431X20154363CrossRefPubMedPubMedCentral

161.

Z. Zhou, X. Zhu, H. Huang, Z. Xu, J. Jiang, B. Chen, H. Zhu, Recent progress of research regarding the applications of stem cells for treating Diabetes Mellitus. Stem Cells Dev. 31, 102–110 (2022). https://doi.org/10.1089/scd.2021.0083CrossRefPubMed

162.

L. Yang, Z.M. Hu, F.X. Jiang, W. Wang, Stem cell therapy for insulin-dependent diabetes: Are we still on the road? World J. Stem Cells 14, 503–512 (2022). https://doi.org/10.4252/wjsc.v14.i7.503CrossRefPubMedPubMedCentral

163.

S. Bourgeois, T. Sawatani, A. Van Mulders, N. De Leu, Y. Heremans, H. Heimberg, M. Cnop, W. Staels, Towards a functional cure for diabetes using stem cell-derived beta cells: are we there yet? Cells. 10 (2021). https://doi.org/10.3390/cells10010191

Titel: The efficiency of stem cell differentiation into functional beta cells for treating insulin-requiring diabetes: Recent advances and current challenges
verfasst von: Yunfei Luo
Peng Yu
Jianping Liu
Publikationsdatum: 10.05.2024
Verlag: Springer US
Erschienen in: Endocrine
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-024-03855-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The efficiency of stem cell differentiation into functional beta cells for treating insulin-requiring diabetes: Recent advances and current challenges

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

Update Innere Medizin